On the basis of previous reports from China, a subset of COVID-19 patients had liver impairment with abnormal levels of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) accompanied by slightly elevated bilirubin levels during disease progression (6–8). This evidence concerns the gene GPT and COVID-19.